Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

SBFM RSS Feed
Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, TraderUsa, Gordon Buffett
Search This Board:
Last Post: 11/27/2014 5:49:41 AM - Followers: 175 - Board type: Free - Posts Today: 2








 



 

 


"The Future Of Medicine"
 

 




 
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 





 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 
 


Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697




 



Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.


Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options




 





 

 



 

 
 
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.







Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 







 
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).




The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.
 






Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug







 



http://sunshinebiopharma.com/investor/press-releases/
 
November 19, 2014
 
 
SUNSHINE BIOPHARMA SIGNS AGREEMENT WITH LONZA TO MANUFACTURE ITS LEAD ANTI-CANCER COMPOUND, Adva-27a
 
 
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
 
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
 
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
 
About Lonza
 
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
 
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
 
 
 

 
 
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
 
About Adva-27a
 
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
 
Safe Harbor Forward-Looking Statements
 
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
 
For Additional Information:
 
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290, colleen.floreck@lonza.com
Constance Ward, +41 61 316 8840, constance.ward@lonza.com
 
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/nansha-china.aspx

Visp Switzerland
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/visp-switzerland.aspx




SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals
 
 

 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

 
Intellectual Property

 
We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
 
 
Advanomics

http://www.canada-companies-info.com/advanomics-corporationcorporation-advanomics-65q2
Advanomics Corporation, the Parent Company of Sunshine Biopharma
 

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada

Tel: 514-764-9698
Fax: 514-764-9699
info@advanomics.com

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:

Adva-27a

Difluoro-Etoposide™
Entering Phase I later this year (Lead Compound)

 

Adva-R46

RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase

 

Adva-33c

Difluoro-Carboplatin™
Currently in preclinical phase



 







SBFM Share Structure
 

From otcmarkets.com and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.
 

Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO




SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

http://corporatestock.com




Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada
Tel: 514-764-9698
Fax: 514-764-9699

http://sunshinebiopharma.com
info@sunshinebiopharma.com


 

 



 


 

 












































































 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SBFM
Current Price
Volume:
Bid Ask Day's Range
Wiki
SBFM News: Current Report Filing (8-k) 11/19/2014 04:01:04 PM
SBFM News: Quarterly Report (10-q) 11/12/2014 07:01:12 AM
SBFM News: Quarterly Report (10-q) 08/12/2014 05:26:36 PM
SBFM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/28/2014 04:05:06 PM
SBFM News: Notice of Effectiveness (effect) 07/24/2014 06:01:50 AM
PostSubject
#18512  Sticky Note November 19, 2014 Delivery of an initial batch BooDog 11/20/14 06:08:06 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#18615   That is a solid signal of what is billdart 11/27/14 05:49:41 AM
#18614   Fundamentals here are strong,only a matter of time billdart 11/27/14 05:40:08 AM
#18613   No news on planet earth,smoke and fly-EOM Cash Monster 11/26/14 06:57:35 PM
#18612   Not one fill for me today. Reminds BooDog 11/26/14 04:13:42 PM
#18611   http://www.bioportfolio.com/news/article/2150845/Sunshine-Biopharma-Inc-SBFM-Fin Lavaliotis 11/26/14 01:22:06 PM
#18610   News out.. Lavaliotis 11/26/14 01:21:34 PM
#18609   Slap the ask! reginaliberta 11/26/14 12:46:59 PM
#18608   They're not letting any bids fill. Ya BooDog 11/26/14 12:04:10 PM
#18607   Hope the stock at least matches the new Citrati 11/26/14 10:13:52 AM
#18606   Sometimes you just need to look at things Gordon Buffett 11/26/14 08:57:35 AM
#18605   Nice dd,this turd can make you a millionaire overnight.EOM Cash Monster 11/26/14 08:13:44 AM
#18604   I am pleased with this development... would be macnqueso 11/26/14 06:07:02 AM
#18603   Can you grow up a little? You talk like clearsudden 11/25/14 09:20:54 PM
#18602   Its called $500 Cosi Di Jacques Cartier Bridge Cash Monster 11/25/14 07:32:01 PM
#18601   If this turd would have the cure to Cash Monster 11/25/14 06:53:48 PM
#18600   Did this turd pay for manufacturing?? Cash Monster 11/25/14 06:12:23 PM
#18599   would love to see the fine print in Kalinn 11/25/14 03:27:15 PM
#18598   I won't be left behind. But I'm BooDog 11/25/14 11:58:29 AM
#18597   Lonza will eventually deliver on manufacturing and this reginaliberta 11/25/14 11:55:44 AM
#18596   Up and away ... Grab the cheapies while reginaliberta 11/25/14 11:26:07 AM
#18595   I can't say I agree more, especially on Gordon Buffett 11/25/14 09:52:58 AM
#18594   Way undervalued here buff billdart 11/25/14 09:19:59 AM
#18593   All joking aside. Lonza deal is the Gordon Buffett 11/25/14 08:46:39 AM
#18592   Let's lift this baby off the ground. Gordon Buffett 11/25/14 08:43:09 AM
#18591   Your watching and waiting for this to move billdart 11/25/14 08:37:51 AM
#18590   With lonza announcing agreement will bring major attention, billdart 11/25/14 07:02:10 AM
#18589   SBFM OOTC on Finra. man this is BooDog 11/25/14 06:23:08 AM
#18588   Just the plant in China is 200,000 square billdart 11/24/14 11:33:56 PM
#18587   Congratulations to management on a job well done billdart 11/24/14 11:26:16 PM
#18586   4.50$ moved the stock up 20% at the Kalinn 11/24/14 06:26:38 PM
#18585   volume is just too low for any form BooDog 11/24/14 04:05:17 PM
#18584   took some nice profits elsewhere today so just BooDog 11/24/14 02:23:41 PM
#18583   Thanks for the thoughts BooDog. I'm still tempted reportmyabuse 11/24/14 02:00:26 PM
#18582   Good Morning... QHP 11/24/14 02:34:25 AM
#18581   Headed sub penny taubytaub 11/23/14 07:49:14 AM
#18580   Hey Boodog! All is good, still chasing a Norton1973 11/22/14 04:39:16 AM
#18579   Hey Norton! flashback! lol. Hope all BooDog 11/21/14 09:12:38 PM
#18578   ......and ? Gordon Buffett 11/21/14 03:50:54 PM
#18577   SBFM, http://www.otcmarkets.com/stock/SBFM/news Norton1973 11/21/14 02:32:19 PM
#18576   ....but still too bad, no reference to SBFM. Gordon Buffett 11/21/14 11:42:26 AM
#18575   Manufacturing will begin at Lonza’s Nansha, China facility BooDog 11/21/14 11:37:16 AM
#18574   Great sticky note ! Gordon Buffett 11/21/14 11:15:31 AM
#18573   not a big fan of 'media contacts'... I'd Kalinn 11/21/14 11:07:03 AM
#18572   When this flies through the .20's I'll be BooDog 11/21/14 10:55:08 AM
#18571   never a good thing when a company is Kalinn 11/21/14 10:45:06 AM
#18570   News going out once the PO is received, Lavaliotis 11/21/14 10:44:20 AM
#18569   Record low with Lonza pr, Jimmythegreek 11/21/14 10:28:34 AM
#18568   Record low ..... What a surprise!!!! Won't be mamushki 11/21/14 10:19:28 AM
#18567   Beta pharma was Bs, just like this pr.Lonza Jimmythegreek 11/21/14 09:31:30 AM
#18566   they know nothing about it,another bogus pr from management. Jimmythegreek 11/21/14 09:20:35 AM
PostSubject